Catalyst Pharmaceutical
CPRX • NASDAQ
Catalyst Pharmaceutical is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Richard John Daly, with a market cap of $2.9B.
CEORichard John Daly
Next Earnings
Upcoming earnings announcement for Catalyst Pharmaceutical
Date
Wednesday, May 6, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
$0.61
Revenue Estimate
$147.2M
Earnings History
Past 12 earnings reports for Catalyst Pharmaceutical
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 25, 2026 | Q4 2025 | $0.68Est: $0.49 | +38.8% | $152.5MEst: $141.7M | +7.7% |  10-K |
| Nov 5, 2025 | Q3 2025 | $0.68Est: $0.51 | +33.3% | $148.4MEst: $136.7M | +8.6% | 10-Q |
| Aug 6, 2025 | Q2 2025 | $0.68Est: $0.55 | +23.6% | $146.6MEst: $139.9M | +4.7% | 10-Q |
| May 7, 2025 | Q1 2025 | $0.68Est: $0.53 | +28.3% | $141.4MEst: $130.9M | +8.1% | 10-Q |
| Feb 26, 2025 | Q4 2024 | $0.70Est: $0.55 | +27.3% | $141.8MEst: $134.2M | +5.7% | 10-K |
| Nov 6, 2024 | Q3 2024 | $0.57Est: $0.30 | +90.0% | $128.7MEst: $123.4M | +4.3% | 10-Q |
| Aug 7, 2024 | Q2 2024 | $0.56Est: $0.26 | +115.4% | $122.7MEst: $112.0M | +9.6% | 10-Q |
| May 8, 2024 | Q1 2024 | $0.38Est: $0.17 | +123.5% | $98.5MEst: $98.1M | +0.4% | 10-Q |
| Feb 28, 2024 | Q4 2023 | $0.53Est: $0.26 | +103.8% | $110.6MEst: $106.1M | +4.2% | 10-K |
| Nov 8, 2023 | Q3 2023 | $0.49Est: $0.44 | +11.4% | $102.7MEst: $100.4M | +2.3% | — |
| Aug 9, 2023 | Q2 2023 | $0.53Est: $0.42 | +26.2% | $99.6MEst: $92.7M | +7.4% | 10-Q |
| May 10, 2023 | Q1 2023 | $0.41Est: $0.32 | +28.1% | $85.4MEst: $81.6M | +4.6% | — |